J 2024

The European Registry for Patients with Mechanical Circulatory Support (EUROMACS): fourth Paediatric EUROMACS (Paedi-EUROMACS) report

ROHDE, Sofie; van Puyvelde JOERI; Kevin M VEEN; Martin SCHWEIGER; Daniel BIERMANN et al.

Základní údaje

Originální název

The European Registry for Patients with Mechanical Circulatory Support (EUROMACS): fourth Paediatric EUROMACS (Paedi-EUROMACS) report

Autoři

ROHDE, Sofie; van Puyvelde JOERI; Kevin M VEEN; Martin SCHWEIGER; Daniel BIERMANN; Antonio AMODEO; Thomas MARTENS; Kevin DAMMAN; Can GOLLMANN-TEPEKOYLU; Michael HULMAN; Attilio IACOVONI; Ulrike S KRAMER; Antonio LOFORTE; Pace Napoleone CARLO; Petr NĚMEC; Ivan NETUKA; Mustafa OZBARAN; Luz POLO; Yuriy PYA; Faiz RAMJANKHAN; Eugen SANDICA; Joanna SLIWKA; Brigitte STILLER; Alexander KADNER; Alessio FRANCESCHINI; Timothy THIRUCHELVAM; Daniel ZIMPFER; Felix BERGER; Ben DAVIES; Alexey DASHKEVICH; Christoffer STARK; Bart MEYNS; Theo M M H DE BY a Oliver MIERA

Vydání

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, CARY, OXFORD UNIV PRESS INC, 2024, 1010-7940

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 3.000

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/24:00137003

Organizační jednotka

Lékařská fakulta

EID Scopus

Klíčová slova anglicky

Mechanical circulatory support; Ventricular assist device; Paediatric; Transplantation; EUROMACS

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 2. 9. 2024 15:10, Mgr. Tereza Miškechová

Anotace

V originále

OBJECTIVES: The use of ventricular assist devices (VADs) in children is increasing. However, absolute numbers in individual centres and countries remain small. Collaborative efforts such as the Paedi-European Registry for Patients with Mechanical Circulatory Support (EUROMACS) are therefore essential for combining international experience with paediatric VADs. Our goal was to present the results from the fourth Paedi-EUROMACS report. METHODS: All paediatric (<19 years) patients from the EUROMACS database supported by a VAD were included. Patients were stratified into a congenital heart disease (CHD) group and a group with a non-congenital aetiology. End points included mortality, a transplant and recovery. Cox proportional hazard models were used to explore associated factors for mortality, cerebrovascular accident and pump thrombosis. RESULTS: A total of 590 primary implants were included. The congenital group was significantly younger (2.5 vs 8.0 years, respectively, P < 0.001) and was more commonly supported by a pulsatile flow device (73.5% vs 59.9%, P < 0.001). Mortality was significantly higher in the congenital group (30.8% vs 20.4%, P = 0.009) than in the non-congenital group. However, in multivariable analyses, CHD was not significantly associated with mortality [hazard ratio (HR) 1.285; confidence interval (CI) 0.8111-2.036, P = 0.740]. Pump thrombosis was the most frequently reported adverse event (377 events in 132 patients; 0.925 events per patient-year) and was significantly associated with body surface area (HR 0.524, CI 0.333-0.823, P = 0.005), CHD (HR 1.641, CI 1.054-2.555, P = 0.028) and pulsatile flow support (HR 2.345, CI 1.406-3.910, P = 0.001) in multivariable analyses. CONCLUSIONS: This fourth Paedi-EUROMACS report highlights the increasing use of paediatric VADs. The patient populations with congenital and non-congenital aetiologies exhibit distinct characteristics and clinical outcomes.